News Briefs

Genetic therapy falls short for Huntington’s Disease
May 8, 2021 - 11:10 am

Two pharmaceutical companies have halted clinical trials of gene-targeting therapies for Huntington’s disease (HD), following the drugs’ disappointing performance.

Researchers had hoped that the treatments—known as antisense oligonucleotides (ASOs)—would be a game changer for HD, an incurable genetic condition that affects cognition, behaviour and movement. But back-to-back announcements from Roche, headquartered in Basel, Switzerland, and Wave Life Sciences, in Cambridge, Massachusetts, have dealt a crushing blow to those affected by the disease.

“I was really shocked, really tearful,” says Marion, a woman in London with HD, who was part of one of the trials. “We didn’t see it coming at all. I felt really frightened and worried about my future.” Marion requested that her last name be withheld to protect her privacy.

Source: Scientific American

News Briefs

Trivia

Sushruta

Sushruta: The father of surgery

Twitter Handle

Copyright © 2020 I Daily Remedy
Powered by: YES IT Labs LLC